Spots Global Cancer Trial Database for biliary tract carcinoma
Every month we try and update this database with for biliary tract carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas | NCT00490399 | Biliary Tract C... | gemcitabine cisplatin | 20 Years - 70 Years | Eli Lilly and Company | |
| First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | NCT05123482 | Breast Cancer Biliary Tract C... Ovarian Cancer Endometrial Can... | AZD8205 | 18 Years - | AstraZeneca | |
| SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma | NCT06199882 | Biliary Tract C... | SBRT Sequential... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| FOLFIRINOX for 2nd-line Treatment of BTC | NCT03778593 | Biliary Tract C... | 5-Fluorouracil Leucovorin Irinotecan Oxaliplatin 5% dextrose wat... | 20 Years - | Dong-A University Hospital | |
| Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma | NCT06168292 | Biliary Tract C... Radiotherapy Radio-frequency... | ID-RFA and Radi... | 20 Years - | National Cancer Center, Korea | |
| Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma | NCT05845554 | Biliary Tract C... | The extracted D... | 18 Years - | Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University | |
| Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer | NCT04984980 | Biliary Tract C... Initially Unres... | Combination of ... | 18 Years - 80 Years | Fudan University | |
| GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma | NCT05668884 | Biliary Tract C... | Combination of ... | 18 Years - 75 Years | Fudan University | |
| A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | NCT02151084 | Biliary Tract C... Gallbladder Car... | Selumetinib Cisplatin Gemcitabine | 18 Years - | University Health Network, Toronto | |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study | NCT04924062 | Biliary Tract C... | Pembrolizumab Gemcitabine Cisplatin Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | NCT06048133 | Biliary Tract C... Cholangiocarcin... Bile Duct Cance... | Gemcitabine Cisplatin Zimberelimab Quemliclustat | 18 Years - | Big Ten Cancer Research Consortium | |
| Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma | NCT05822453 | Biliary Tract C... | Gemcitabine S1 Tislelizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) | NCT04003636 | Biliary Tract C... | Pembrolizumab Gemcitabine Cisplatin Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Apatinib for Advanced Biliary Carcinoma | NCT03427242 | Biliary Tract N... | Apatinib | 18 Years - 70 Years | Fudan University | |
| Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer | NCT04984980 | Biliary Tract C... Initially Unres... | Combination of ... | 18 Years - 80 Years | Fudan University | |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | NCT03027284 | Advanced Cancer Metastatic Canc... Biliary Tract C... Cholangiocarcin... Gall Bladder Ca... Solid Tumor Non-Hodgkin's L... | Merestinib Cisplatin Gemcitabine | 20 Years - | Eli Lilly and Company | |
| Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma | NCT05845554 | Biliary Tract C... | The extracted D... | 18 Years - | Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University | |
| Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma | NCT06430827 | Biliary Tract C... | irinotecan hydr... Capecitabine | 18 Years - | Peking Union Medical College Hospital | |
| GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC | NCT05023109 | Biliary Tract C... | GP+PD-1+Tight | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | NCT04003896 | Biliary Tract C... | Abemaciclib | 18 Years - | Milton S. Hershey Medical Center | |
| Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer | NCT04067960 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Biliary Tract C... Clinical Stage ... Clinical Stage ... Malignant Brain... Malignant Genit... Malignant Solid... Pancreatobiliar... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Color... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage IIIA Colo... Stage IIIA Ovar... Stage IIIA Pros... Stage IIIB Colo... Stage IIIB Ovar... Stage IIIB Pros... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Pros... Stage IV Colore... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IVA Color... Stage IVA Ovari... Stage IVA Pancr... Stage IVA Prost... Stage IVB Color... Stage IVB Ovari... Stage IVB Pancr... Stage IVB Prost... Stage IVC Color... | Biospecimen Col... Genetic Testing Quality-of-Life... Questionnaire A... | - | Mayo Clinic | |
| Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas | NCT00490399 | Biliary Tract C... | gemcitabine cisplatin | 20 Years - 70 Years | Eli Lilly and Company | |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) | NCT04003636 | Biliary Tract C... | Pembrolizumab Gemcitabine Cisplatin Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | NCT04003896 | Biliary Tract C... | Abemaciclib | 18 Years - | Milton S. Hershey Medical Center | |
| Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma | NCT06168292 | Biliary Tract C... Radiotherapy Radio-frequency... | ID-RFA and Radi... | 20 Years - | National Cancer Center, Korea | |
| A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma | NCT05064852 | Biliary Tract C... | Surufatinib | 18 Years - | Qilu Hospital of Shandong University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
